Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
August 04 2022 - 6:30AM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, announced today that it
will release second quarter 2022 results and corporate update on
Thursday, August 11, 2022. The Company will host a conference call
at 8:30 a.m. Eastern Daylight Time.
The conference call will be available via phone
and webcast. To access the call, please dial +1 (866) 374-5140 for
U.S. callers, or +1 (404) 400-0571 for international callers, and
use PIN : 54780189# approximately 15 minutes prior to the call. To
access the live audio webcast of the conference call please visit
the “Investors” section of the Company’s website at
https://www.affimed.com/investors/webcasts-and-corporate-presentation/.
A replay of the call will be archived on Affimed’s website for 30
days after the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer by actualizing the untapped
potential of the innate immune system. The Company’s proprietary
ROCK® platform enables a tumor-targeted approach to recognize and
kill a range of hematologic and solid tumors, enabling a broad
pipeline of wholly-owned and partnered single agent and combination
therapy programs. The ROCK® platform predictably generates
customized innate cell engager (ICE®) molecules, which use
patients’ immune cells to destroy tumor cells. This innovative
approach enabled Affimed to become the first company with a
clinical-stage ICE®. Headquartered in Heidelberg, Germany, with
offices in New York, NY, Affimed is led by an experienced team of
biotechnology and pharmaceutical leaders united by a bold vision to
stop cancer from ever derailing patients’ lives. For more about the
Company’s people, pipeline and partners, please visit:
www.affimed.com.
Investor Relations ContactAlexander
FudukidisDirector, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024